Blunted increase in plasma BNP during acute coronary syndrome attacks in obese patients
Blunted increase in plasma BNP in response to cardiac hemodynamic stress during ACS attacks was observed in obese individuals. In addition to the relatively low plasma BNP levels at baseline in obese individuals, the blunted response of BNP elevation to ACS attacks may have important pathophysiological implications for hemodynamic regulation and myocardial energy metabolism.
Authors
- Makoto Kawai (ORCID: https://orcid.org/0000-0002-0914-9376)
- Kosuke Minai (ORCID: https://orcid.org/0000-0002-5327-3016)
- Yuhei Oi
- Tomohisa Nagoshi (ORCID: https://orcid.org/0000-0002-8980-881X)
- Takayuki Ogawa (ORCID: https://orcid.org/0000-0002-7424-6885)
- Toshikazu Tanaka (ORCID: https://orcid.org/0000-0002-0711-7880)
- Toraaki Okuyama
- Haruka Kimura (ORCID: https://orcid.org/0000-0001-7477-5819)
- Nana Hiraki (ORCID: https://orcid.org/0009-0001-5577-6549)
- Kazuo Ogawa (ORCID: https://orcid.org/0000-0003-4263-6421)
- Michihiro Yoshimura (ORCID: https://orcid.org/0000-0003-2828-7229)
- Yusuke Kashiwagi
Institutions
- Jikei University School of Medicine (JP)
Publication Details
- Journal
- IJC Heart & Vasculature
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1016/j.ijcha.2024.101508
- Citations
- 3
- Primary Topic
- Cardiac Arrest and Resuscitation
- Type
- article
- Field-Weighted Citation Impact
- 2.07
Funders
- AstraZeneca
- Kowa Company
- Boehringer Ingelheim Japan
- Toa Eiyo
- Ministry of Education, Culture, Sports, Science and Technology
- Novo Nordisk
- Astellas Pharma
- Otsuka Pharmaceutical
- Astellas Foundation for Research on Metabolic Disorders
- SENSHIN Medical Research Foundation
- Novartis Pharma
- Bayer Yakuhin
- Novo Nordisk Pharma
- Daiichi Sankyo Europe